Show simple item record

dc.contributor.authorMcDaniel, AS
dc.contributor.authorFerraldeschi, R
dc.contributor.authorKrupa, R
dc.contributor.authorLanders, M
dc.contributor.authorGraf, R
dc.contributor.authorLouw, J
dc.contributor.authorJendrisak, A
dc.contributor.authorBales, N
dc.contributor.authorMarrinucci, D
dc.contributor.authorZafeiriou, Z
dc.contributor.authorFlohr, P
dc.contributor.authorSideris, S
dc.contributor.authorCrespo, M
dc.contributor.authorFigueiredo, I
dc.contributor.authorMateo, J
dc.contributor.authorde Bono, JS
dc.contributor.authorDittamore, R
dc.contributor.authorTomlins, SA
dc.contributor.authorAttard, G
dc.date.accessioned2016-09-28T12:01:11Z
dc.date.issued2017-11
dc.identifier.citationBJU international, 2017, 120 (5B), pp. E30 - E44
dc.identifier.issn1464-4096
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/137
dc.identifier.eissn1464-410X
dc.identifier.doi10.1111/bju.13631
dc.description.abstractObjectives To use a non-biased assay for circulating tumour cells (CTCs) in patients with prostate cancer (PCa) in order to identify non-traditional CTC phenotypes potentially excluded by conventional detection methods that are reliant on antigen- and/or size-based enrichment.Patients and methods A total of 41 patients with metastatic castration-resistant PCa (mCRPC) and 20 healthy volunteers were analysed on the Epic CTC platform, via high-throughput imaging of DAPI expression and CD45/cytokeratin (CK) immunofluorescence (IF) on all circulating nucleated cells plated on glass slides. To confirm the PCa origin of CTCs, IF was used for androgen receptor (AR) expression and fluorescence in situ hybridization was used for PTEN and ERG assessment.Results Traditional CTCs (CD45 - /CK + /morphologically distinct) were identified in all patients with mCRPC and we also identified CTC clusters and non-traditional CTCs in patients with mCRPC, including CK - and apoptotic CTCs. Small CTCs (≤white blood cell size) were identified in 98% of patients with mCRPC. Total, traditional and non-traditional CTCs were significantly increased in patients who were deceased vs alive after 18 months; however, only non-traditional CTCs were associated with overall survival. Traditional and total CTC counts according to the Epic platform in the mCRPC cohort were also significantly correlated with CTC counts according to the CellSearch system.Conclusions Heterogeneous non-traditional CTC populations are frequent in mCRPC and may provide additional prognostic or predictive information.
dc.formatPrint-Electronic
dc.format.extentE30 - E44
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectNeoplasm Metastasis
dc.subjectDisease Progression
dc.subjectProstate-Specific Antigen
dc.subjectReceptors, Androgen
dc.subjectIn Situ Hybridization, Fluorescence
dc.subjectPhenotype
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectPTEN Phosphohydrolase
dc.subjectNeoplastic Cells, Circulating
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.subjectBiomarkers, Tumor
dc.titlePhenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
dc.typeJournal Article
rioxxterms.versionofrecord10.1111/bju.13631
rioxxterms.licenseref.startdate2017-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBJU international
pubs.issue5B
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.publication-statusPublished
pubs.volume120
pubs.embargo.termsNo embargo
icr.researchteamCancer Biomarkersen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamTreatment Resistanceen_US
dc.contributor.icrauthorAttard, Gerhardten
dc.contributor.icrauthorDe Bono, Johannen
dc.contributor.icrauthorCrespo, Mateusen
dc.contributor.icrauthorMateo Valderrama, Joaquinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record